跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
簡 麗年
教授
衛生福利研究所
https://orcid.org/0000-0001-9441-552X
電話
02-2826-7000#67066
電子郵件
linien.chien
nycu.edu
tw
h-index
h10-index
h5-index
1312
引文
20
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
979
引文
19
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
315
引文
10
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2003
2024
每年研究成果
概覽
指紋
網路
研究成果
(102)
類似的個人檔案
(6)
指紋
查看啟用 Li-Nien Chien 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Acute Myocardial Infarction
26%
Adjusted Hazard Ratio
29%
Adjusted Odds Ratio
7%
All-cause Mortality
10%
Anemia
10%
Aspirin
9%
Breast Cancer Prevention
16%
Cervical Cancer
8%
Cervical Cancer Prevention
17%
Chronic Obstructive Pulmonary Disease
10%
Clinical Outcomes
8%
Comorbidity
8%
Confidence Interval
61%
Dementia Risk
9%
Drug-eluting Stent
15%
Drug-eluting Stent Implantation
12%
Dry Eye
9%
End-stage Renal Disease
14%
Epidemiology
9%
Georgia
15%
High Risk
12%
Hospitalization
13%
Incidence Rate
9%
Ischemic Stroke
12%
Kidney Disease Progression
9%
Low Risk
14%
Medicaid
13%
Metformin
10%
Myocardial Infarction
8%
National Cohort Study
48%
National Health Insurance Research Database (NHIRD)
13%
Nested Case-control Study
19%
Newly Diagnosed
11%
Parkinson's Disease
15%
Patients with Diabetes
12%
Percutaneous Coronary Intervention
14%
Population-based
8%
Population-based Cohort Study
36%
Population-based Study
17%
Post-stroke Epilepsy
9%
Risk Factors
12%
ST-elevation Myocardial Infarction (STEMI)
15%
Subdistribution Hazard Ratio
8%
Taiwan
100%
Taiwan National Health Insurance Research Database
10%
Taiwanese
7%
Total Hip Replacement
9%
Treatment Patterns
10%
Type 1 Diabetes Mellitus (T1DM)
8%
Type 2 Diabetes Mellitus (T2DM)
8%
Pharmacology, Toxicology and Pharmaceutical Science
Acetylsalicylic Acid
10%
Acute Heart Infarction
26%
Acute Myeloid Leukemia
6%
All Cause Mortality
5%
Alzheimer's Disease
6%
Anticonvulsive Agent
6%
Antiplatelet
10%
Atrial Fibrillation
10%
Bleeding
9%
Brain Ischemia
12%
Breast Cancer
13%
Cancer Registry
5%
Cardiogenic Shock
6%
Cardiovascular Disease
6%
Case-Control Study
16%
Cerebrovascular Accident
22%
Chemotherapy
5%
Chronic Obstructive Lung Disease
13%
Clopidogrel
6%
Cohort Study
57%
Comorbidity
13%
Congestive Heart Failure
11%
Diabetes Mellitus
8%
Diseases
13%
Dry Eye
9%
End Stage Renal Disease
13%
Eye Disease
9%
Gastroesophageal Reflux
6%
Glaucoma
6%
Heart Infarction
11%
Hemodialysis
9%
Kidney Disease
7%
Metformin
10%
New-Onset Atrial Fibrillation
6%
Non Insulin Dependent Diabetes Mellitus
16%
Non ST Segment Elevation Myocardial Infarction
8%
Parkinson's Disease
10%
Phenytoin
6%
Respiratory Failure
6%
Rivaroxaban
6%
Sodium Valproate
7%
ST Segment Elevation Myocardial Infarction
7%
Statin (Protein)
6%
Survival Rate
5%
Uterine Cervix Cancer
13%
Warfarin
6%
Medicine and Dentistry
Acute Heart Infarction
12%
Acute Myeloid Leukemia
6%
Alzheimer's Disease
6%
Anemia
9%
Antiplatelet
5%
Apoplexy
16%
Autism
6%
Brain Ischemia
10%
Breast Cancer
11%
Breast Cancer Prevention
16%
Cancer Registry
6%
Cancer Therapy
19%
Cardiogenic Shock
6%
Case-Control Study
10%
Cervical Cancer
9%
Cervical Cancer Prevention
16%
Charlson Comorbidity Index
5%
Chronic Obstructive Pulmonary Disease
9%
Cohort Analysis
37%
Cohort Effect
9%
Combination Therapy
5%
Comorbidity
11%
Compression Fracture
6%
Congestive Heart Failure
9%
Diabetes Mellitus
5%
Diseases
10%
Drug-Eluting Stent
16%
Dry Eye
6%
End Stage Renal Disease
8%
Eye Disease
6%
Hazard Ratio
29%
Hemodialysis
6%
Hip Replacement
6%
Medicaid
7%
Nephropathy
6%
New-Onset Atrial Fibrillation
6%
Overall Survival
6%
Parkinson's Disease
10%
Percutaneous Coronary Intervention
6%
Percutaneous Vertebroplasty
6%
Proportional Hazards Model
7%
Proton-Pump Inhibitor
6%
Reoperation
7%
Respiratory Failure
5%
Retrospective Cohort Study
5%
ST Segment Elevation Myocardial Infarction
5%
Surgeon
6%
Survival Rate
6%
Womens Health
6%
